Arsenic Bioaccessibility of Realgar Influenced by the Other Traditional Chinese Medicines in Niuhuang Jiedu Tablet and the Roles of Gut Microbiota.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

1. Bioaccessibility and Health Risk Assessment of Arsenic in Realgar-Containing Traditional Chinese Medicines.Biological trace element research · 2026
   Article
2. Compatibility of Niuhuang Jiedu Tablets Results in Attenuated Arsenic Bioaccumulation and Consequent Protection against Realgar-Induced Toxicity in Mice.Evidence-based complementary and alternative medicine : eCAM · 2022
   Article
3. Arsenic Accumulation of Realgar Altered by Disruption of Gut Microbiota in Mice.Evidence-based complementary and alternative medicine : eCAM · 2020
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

5 authors at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract